Baidu
map

Blood:周晋等提出亚砷酸抗白血病给药新方式

2012-01-01 MedSci原创 MedSci原创

近日,国际著名杂志Blood刊登了哈尔滨医科大学科研人员的最新研究成果“Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells。”,研究人员经过10年攻关,在亚砷酸抗白血病研究中取得了

近日,国际著名杂志Blood刊登了哈尔滨医科大学科研人员的最新研究成果“Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells。”,研究人员经过10年攻关,在亚砷酸抗白血病研究中取得了可喜进展。他们首次“锁定”了亚砷酸作用的3个细胞膜靶点,并提出了“亚砷酸持续缓慢输注法”和“数学模型控制下的甘露醇助透法”两种高效低毒的给药方式,疗效十分明显。

为进一步揭示亚砷酸抗白血病的机制,哈医大附属一院血液科主任周晋教授指导的课题组在国家自然科学基金的支持下,从2001年开始针对细胞膜离子通道、酶活性变化、砷代谢等问题进行了深入系统的研究。先后发现了亚砷酸的3个细胞膜靶点(HERG钾通道、L-型钙通道、PKC激酶)和1个亚砷酸线粒体基因靶点(D-LOOP区),实验证明正是这些靶点引起了亚砷酸细胞毒损伤,加重了对心脏血管系统的不良刺激,产生副作用并影响亚砷酸的疗效。

该成果日前获黑龙江省科技进步奖一等奖。目前,哈医大一院正继续扩大临床样本,并将此方法推广到对癌性胸水和肝癌的动脉内持续灌注等实体瘤的临床治疗。(生物谷Bioon.com)

Phagocytosis by macrophages and endothelial cells inhibits procoagulant and fibrinolytic activity of acute promyelocytic leukemia cells

Rui Xie1, Chunyan Gao1, Wen Li1, Jiuxin Zhu1, Valerie Novakovic2, Jing Wang1, Ruishuang Ma1, Jin Zhou1, Gary E. Gilbert2, and Jialan Shi2,*

The coagulopathy of acute promyelocytic leukemia (APL) is mainly related to procoagulant substances and fibrinolytic activators of APL blasts, but the fate of these leukemic cells is unknown. The aim of this study was to investigate the removal of APL blasts by macrophages and endothelial cells in vitro and consequent procoagulant and fibrinolytic activity of APL cells. We found that human umbilical vein endothelial cells as well as THP-1 and monocyte-derived macrophages bound, engulfed and subsequently degraded immortalized APL cell line NB4 and primary APL cells. Lactadherin promoted phagocytosis of APL cells in a time-dependent fashion. Furthermore, factor Xa and prothrombinase activity of PS-exposed target APL cells was time-dependently decreased after incubation with phagocytes (THP-1-derived macrophages or human umbilical vein endothelial cells). Thrombin production on target APL cells was reduced by 40-45% after two hours of coincubation with phagocytes, and 80% by a combination of lactadherin and phagocytes. Moreover, plasmin generation of target APL cells was inhibited 30% by two hours of phagocytosis, and approximately 50% by lactadherin-mediated engulfment. These results suggest that engulfment by macrophages and endothelial cells reduce procoagulant and fibrinolytic activity of APL blasts. Lactadherin and phagocytosis could cooperatively ameliorate the clotting disorders in APL.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2070197, encodeId=337020e019788, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Jan 26 23:27:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3893, encodeId=8baa389346, content=Your's is the itnelilgnet approach to this issue., beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=darrence, createdTime=Fri Jan 06 02:37:00 CST 2012, time=2012-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595948, encodeId=7766159594819, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 02 15:27:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2070197, encodeId=337020e019788, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Jan 26 23:27:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3893, encodeId=8baa389346, content=Your's is the itnelilgnet approach to this issue., beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=darrence, createdTime=Fri Jan 06 02:37:00 CST 2012, time=2012-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595948, encodeId=7766159594819, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 02 15:27:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
    2012-01-06 darrence

    Your's is the itnelilgnet approach to this issue.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2070197, encodeId=337020e019788, content=<a href='/topic/show?id=c4b45838618' target=_blank style='color:#2F92EE;'>#新方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58386, encryptionId=c4b45838618, topicName=新方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Jan 26 23:27:00 CST 2012, time=2012-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=3893, encodeId=8baa389346, content=Your's is the itnelilgnet approach to this issue., beContent=null, objectType=article, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=darrence, createdTime=Fri Jan 06 02:37:00 CST 2012, time=2012-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595948, encodeId=7766159594819, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jan 02 15:27:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
    2012-01-02 智智灵药
Baidu
map
Baidu
map
Baidu
map